Abstracts tagged "Scleredema"

Abstract Number: 1887 • 2016 ACR/ARHP Annual Meeting
Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis
Mariana Freschi Bombini¹, Fernando A. Peres², Nailu A. Sinicato³, Aline Tamires Lapa², Leticia Rittner⁴, Roberto Souza⁵, Ana Paula del Rio¹, João Francisco Marques-Neto¹ and Simone Appenzeller¹, ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³Pediatrics, State University of Campinas, Campinas, Brazil, ⁴Electrical Engineering, State University of Campinas, Campinas, Brazil, ⁵State University of Campinas, campinas, Brazil
Background/Purpose: Several factors has been described as responsible for the association between olfactory impairment and brain regions. In systemic sclerosis (SSc) the olfactory interaction has…
Abstract Number: 822 • 2015 ACR/ARHP Annual Meeting
Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
Sei-ichiro Motegi¹, Kazuya Yamada¹, Sayaka Toki¹, Akihiko Uchiyama¹, Tetsuya Nakamura² and Osamu Ishikawa¹, ¹Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan, ²Clinical Investigation and Research Unit, Gunma University Graduate School of Medicine, Gunma, Japan
Background/Purpose: Systemic scleroderma (SSc) is a generalized connective tissue disease characterized by fibrosis of the skin and internal organs, vascular dysfunction and immune disorder. Patients…
Abstract Number: 851 • 2015 ACR/ARHP Annual Meeting
Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
Michael Hughes¹, Chris Roberts², Andrew Tracey¹, Graham Dinsdale¹, Andrea Murray¹ and Ariane L. Herrick¹, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, United Kingdom
Background/Purpose: Digital ulcers (DUs) are often a primary end point in SSc clinical trials, although the reliability of rheumatologists grading DUs is poor to moderate…
Abstract Number: 1123 • 2015 ACR/ARHP Annual Meeting
Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner
Ayumi Yoshizaki¹, Takashi Taniguchi¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Yoshihide Asano² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Immune cells play a critical role in systemic sclerosis (SSc). B cells have more functions than producing antibodies, including antigen-presentation, various cytokine production, and…
Abstract Number: 1873 • 2015 ACR/ARHP Annual Meeting
Inter and Intrarater Reliability of the Modified Rodnan Skin Score in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Shervin Assassi³, Elana J. Bernstein⁴, Robyn T. Domsic⁵, Faye N. Hant⁶, Monique E. Hinchcliff⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Tracy M. Frech¹⁰ and Dinesh Khanna¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁸University of Michigan, Ann Arbor, MI, ⁹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: The Modified Rodnan Skin Score (MRSS) is a semiquantitative assessment of skin thickness which is a commonly used outcome measure in Systemic Sclerosis (SSc)…
Abstract Number: 2152 • 2015 ACR/ARHP Annual Meeting
Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases
Elena Pachera¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj³, Rucsandra Dobrota⁴, Matthias Brock⁵, Serena Vettori⁶, Claus Hellerbrand⁷, Carol A. Feghali-Bostwick⁸, Jeorg HW Distler⁹, Gabriela Kania¹⁰ and Oliver Distler¹¹, ¹Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, Schileren, Switzerland, ²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Pulmonology, University Hospital Zurich, Schileren, Switzerland, ⁶Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁷Department of Internal Medicine I, University of Regensburg, Regensburg, Germany, ⁸Medicine, University of Pittsburgh, Pittsburgh, PA, ⁹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, ¹¹Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (LncRNAs) are emerging as a novel class of noncoding transcripts involved in the regulation of gene expression. So far, for only…
Abstract Number: 2153 • 2015 ACR/ARHP Annual Meeting
Nintedanib Ameliorates Fibrotic and Vascular Manifestations in Preclinical Models of Systemic Sclerosis
Jingang Huang¹, Christian Beyer¹, Yun Zhang¹, Katrin Palumbo-Zerr², Clara Dees¹, Oliver Distler³, Georg A. Schett⁴, Stefan Lutz Wollin⁵ and Jorg HW. Distler¹, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology, Research of Systemic Autoimmune Diseases, University Hospital Zurich, Zurich, Switzerland, ⁴Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Boehringer-Ingelheim Pharma, Div. Research Germany, Bad Biberach, Germany
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that inhibits PDGF-, FGFR-, VEGFR-receptors and Src kinases. Nintedanib has recently been approved for the treatment of idiopathic…
Abstract Number: 3131 • 2015 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis
Minghua Wu¹, Gloria Salazar¹, Xiaodong Zhou², Xinjian Guo², John D. Reveille³, Sandeep K. Agarwal⁴, Michael R. Blackburn⁵, Maureen D Mayes¹ and Shervin Assassi¹, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Internal Medicine, University of Texas Medical School at Houston, Houston, TX, ³Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁴Internal Med, Rheumatology, Baylor College of Medicine, Houston, TX, ⁵Biochemistry and Molecular Biology, The University of Texas Medical School at Houston, Houston, TX
Background/Purpose: A recent global gene expression profile study in a large early SSc patient samples revealed a type I interferon (IFN) signature. Type I IFN…
Abstract Number: 3132 • 2015 ACR/ARHP Annual Meeting
Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors
Pei-Suen Tsou^1,2, M. Asif Amin³, Elena Schiopu^2,4, David A. Fox³, Dinesh Khanna^1,2 and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Scleroderma Program, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease characterized by inflammation, vascular complications, and excessive deposition of extracellular matrix. Vascular dysfunction represents a disease initiating event…
Abstract Number: 3006 • 2014 ACR/ARHP Annual Meeting
Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma
Pei-Suen Tsou¹, George Zakhem², Beatrix Balogh², M. Asif Amin³, Phillip Campbell⁴, Gautam Edhayan³, Ray A. Ohara³, Elena Schiopu³, Dinesh Khanna¹, Alisa E. Koch^2,5 and David A. Fox³, ¹University of Michigan Scleroderma Program, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Department of Veteran's Affairs and University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease characterized by inflammation, vasculopathy, and excessive deposition of extracellular matrix. Various studies have demonstrated a paradoxical increase in…
Abstract Number: 1685 • 2014 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Michael Pham¹ and W Leroy Griffing², ¹Division of Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Division of Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Interstitial lung disease remains a primary driver of morbidity and mortality in patients suffering from systemic sclerosis. Cyclophosphamide currently is the treatment with the…
Abstract Number: 966 • 2014 ACR/ARHP Annual Meeting
Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism
Feng Fang¹, Roberta G. Marangoni¹, Xingchun Zhou², Wen Hong³, Boping Ye³, Asano Yoshihide⁴, Shinichi Sato⁵, Yuri Masui⁶, Chengning Zhang⁷, Katja Lakota⁸, Jun Wei⁹, Monique E. Hinchcliff⁷, Philipp Scherer¹⁰, Laszlo Otvos¹¹ and John Varga¹², ¹Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²College of Life and Science, China Pharmaceutical University, Nanjing, China, ³China Pharmaceutical University, Nanjing, China, ⁴University of Tokyo, Tokyo, Japan, ⁵Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan, ⁶Department of Dermatology, University of Tokyo, Tokyo, Japan, ⁷Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁸Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁹Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Texas Southwestern Medical Center, Dallas, TX, ¹¹Temple University, Philadelphia, PA, ¹²Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose :Systemic sclerosis (SSc) skin fibrosis is associated with attenuated cutaneous adipose tissue and adipogenic gene expression. Levels of the adipose-derived cytokine adiponectin (APN) and…
Abstract Number: 762 • 2014 ACR/ARHP Annual Meeting
IQGAP1 Enhances Contractility of Scleroderma Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fibrosis
Tanjina Akter¹, Ilia Atanelishvili², Yuichiro Shirai³, Sybil Prince Nelson⁴, Alvaro Garcia-Martos⁵, Thomas A. Morinelli³, Richard M. Silver⁶ and Galina S. Bogatkevich¹, ¹Department of Rheumatology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ³Medical University of South Carolina,Charleston,USA, chareston, SC, ⁴College of Graduate Studies, Medical University of South Carolina,Charleston,USA, chareston, SC, ⁵Hospital la Zarzuela,Madrid,Spain, Madrid, Spain, ⁶Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC
Background/Purpose Scleroderma associated interstitial lung disease (SSc-ILD) is an irreversible and progressive complication and a leading cause of death among SSc patients. Constitutive overexpression of…
Abstract Number: 903 • 2013 ACR/ARHP Annual Meeting
A Qualitative Study Of The Educational Needs Of Children With Scleroderma and Their Parents
Cindy F. Mendelson¹, Ana-Alicia Huerta², Jane Kastning³, Bernadette Vargas³ and Janet L. Poole⁴, ¹College of Nursing, University of New Mexico, Albuquerque, NM, ²Univeristy of New Mexico, Albuquerque, NM, ³Occupational Therapy, University of New Mexico, Albuquerque, NM, ⁴Occupational Therapy Program, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma is a rare disease, especially in childhood. Skin changes can be physically disfiguring which can lead to lowered self-esteem, especially during the adolescent…
Abstract Number: 820 • 2013 ACR/ARHP Annual Meeting
CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Jörg HW Distler¹, Yongqing Wang², Pawel Zerr³, Katrin Palumbo⁴, Gerald Horan⁵, Peter Schafer⁵ and Bashar Kahaleh⁶, ¹Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medicine, University of Toledo, Toledo, OH, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ, ⁶Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disease in which B cells may play a crucial role in pathogenesis. CC-220 is an immunomodulatory drug…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].